摘要
目的探究丁苯酞联合奥拉西坦对脑梗死后认知障碍患者神经功能以及认知功能的影响。方法90例脑梗死后认知障碍患者,采用计算机随机分为观察组和对照组,每组45例。对照组患者接受奥拉西坦治疗,观察组患者接受丁苯酞联合奥拉西坦治疗。比较两组患者的美国国立卫生研究院卒中量表(NIHSS)评分、简易智力状态检查量表(MMSE)评分、蒙特利尔认知评估量表(MoCA)评分。结果治疗前,两组患者的NIHSS评分比较差异无统计学意义(P>0.05);治疗1、2周后,观察组患者的NIHSS评分分别为(6.75±0.69)、(5.42±0.39)分,均显著低于对照组的(7.85±0.49)、(6.20±0.26)分,差异具有统计学意义(P<0.05)。治疗前,两组患者的MMSE评分比较差异无统计学意义(P>0.05);治疗1、2周后,观察组患者的MMSE评分分别为(18.46±2.72)、(22.49±2.52)分,均显著高于对照组的(16.06±2.43)、(20.43±2.39)分,差异具有统计学意义(P<0.05)。治疗前,两组患者的视空间与执行力、语言功能、注意力、延迟回忆、抽象概括能力、定向力、命名评分及MoCA总分比较差异无统计学意义(P>0.05);治疗2周后,观察组患者的视空间与执行力、语言功能、注意力、延迟回忆、抽象概括能力、定向力、命名评分及MoCA总分分别为(3.96±0.53)、(2.65±0.85)、(4.86±0.35)、(4.64±0.56)、(1.86±0.24)、(5.90±0.55)、(2.79±0.16)、(26.66±3.19)分,均高于对照组的(3.55±0.62)、(1.96±0.67)、(4.12±0.61)、(2.74±0.49)、(1.52±0.33)、(5.16±0.45)、(2.43±0.34)、(21.48±3.42)分,差异具有统计学意义(P<0.05)。结论丁苯酞联合奥拉西坦对脑梗死后认知障碍患者神经功能与认知功能的改善效果显著,值得临床应用。
Objective To investigate the effect of butylphthalide combined with oxiracetam on neurological function and cognitive function in patients with cognitive impairment after cerebral infarction.Methods A total of 90 patients with cognitive impairment after cerebral infarction were randomly divided into observation group and control group by computer,with 45 cases in each group.The control group was treated with oxiracetam,and the observation group was treated with butylphthalide and oxiracetam.The scores of the National Institutes of Health Stroke Scale(NIHSS),the Mini-Mental State Examination Scale(MMSE)and the Montreal Cognitive Assessment Scale(MoCA)were compared between the two groups.Results After 1 and 2 weeks of treatment,NIHSS scores of the observation group were(6.75±0.69)and(5.42±0.39)points,which were significantly lower than those of(7.85±0.49)and(6.20±0.26)points of the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in MMSE score between the two groups(P>0.05).After 1 and 2 weeks of treatment,MMSE scores of the observation group were(18.46±2.72)and(22.49±2.52)points,which were significantly higher than those of(16.06±2.43)and(20.43±2.39)points of the control group,and the differences were statistically significant(P<0.05).Before treatment,there were no statistically significant differences in scores of visual space and executive force,language function,attention,delayed recall,abstract generalization ability,directive force,naming and MoCA score between the two groups(P>0.05).After 2 weeks of treatment,the scores of visual space and executive force,language function,attention,delayed recall,abstract generalization ability,directive force,naming and MoCA score were(3.96±0.53),(2.65±0.85),(4.86±0.35),(4.64±0.56),(1.86±0.24),(5.90±0.55),(2.79±0.16)and(26.66±3.19)points in the observation group,which were higher than those of(3.55±0.62),(1.96±0.67),(4.12±0.61),(2.74±0.49),(1.52±0.33),(5.16±0.45
作者
李睿钧
王健
黄伟佳
张诗琦
肖曼红
LI Rui-jun;WANG Jian;HUANG Wei-jia(Pharmacy Department,Guangzhou Dongsheng Hospital,Guangzhou 510700,China)
出处
《中国现代药物应用》
2023年第20期16-19,共4页
Chinese Journal of Modern Drug Application
基金
丁苯酞联合奥拉西坦治疗脑卒中后认知功能障碍的临床研究(项目编号:202201011586)。
关键词
奥拉西坦
丁苯酞
脑梗死后认知障碍
神经功能
认知功能
Oxiracetam
Butylphthalide
Cognitive impairment after cerebral infarction
Neurological function
Cognitive function
